Investigation of autoantibody profiles for cerebrospinal fluid biomarker discovery in patients with relapsing-remitting multiple sclerosis

Journal of Neuroimmunology

Volumn 242, Issue 1-2, 2012, Pages 26-32

  Beyer, Natascha Helena ^a   Lueking, Angelika ^b   Kowald, Axel ^b   Frederiksen, Jette Lautrup ^c   Heegaard, Niels H H ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b PROTAGEN AG   (Germany)

^c GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Autoantibody profiling; Biomarker; Cerebrospinal fluid; Multiple sclerosis

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; BIOLOGICAL MARKER; IMMUNOGLOBULIN G; RECOMBINANT PROTEIN;

ADULT; AGED; ANTIGEN ANTIBODY REACTION; ARTICLE; AUTOREACTIVITY; CEREBROSPINAL FLUID EXAMINATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; FEMALE; HUMAN; IMMUNOREACTIVITY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

ADULT; AGED; ANTIGEN-ANTIBODY REACTIONS; AUTOANTIBODIES; AUTOANTIGENS; BIOLOGICAL MARKERS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDE LIBRARY; PROTEIN ARRAY ANALYSIS; YOUNG ADULT;

EID: 84856793453     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2011.08.013     Document Type: Article

References (83)

1. Acarin N., Rio J., Fernandez A.L., Tintore M., Duran I., Galan I., Montalban X. Different antiganglioside antibody pattern between relapsing-remitting and progressive multiple sclerosis. Acta Neurol. Scand. 1996, 93(2-3):99-103. available from: PM:8741126.
2. Agius M.A., Kirvan C.A., Schafer A.L., Gudipati E., Zhu S. High prevalence of anti-alpha-crystallin antibodies in multiple sclerosis: correlation with severity and activity of disease. Acta Neurol. Scand. 1999, 100(3):139-147. available from: PM:10478576.
3. Almeras L., Lefranc D., Drobecq H., de Seze J., Dubucquoi S., Vermersch P., Prin L. New antigenic candidates in multiple sclerosis: identification by serological proteome analysis. Proteomics 2004, 4(7):2184-2194. available from: PM:15221778.
4. Archelos J.J., Trotter J., Previtali S., Weissbrich B., Toyka K.V., Hartung H.P. Isolation and characterization of an oligodendrocyte precursor-derived B-cell epitope in multiple sclerosis. Ann. Neurol. 1998, 43(1):15-24. available from: PM:9450764.
5. Baig S., Olsson T., Yu-Ping J., Hojeberg B., Cruz M., Link H. Multiple sclerosis: cells secreting antibodies against myelin-associated glycoprotein are present in cerebrospinal fluid. Scand. J. Immunol. 1991, 33(1):73-79. available from: PM:1705050.
6. Banki K., Colombo E., Sia F., Halladay D., Mattson D.H., Tatum A.H., Massa P.T., Phillips P.E., Perl A. Oligodendrocyte-specific expression and autoantigenicity of transaldolase in multiple sclerosis. J. Exp. Med. 1994, 180(5):1649-1663. available from: PM:7964452.
7. Bartos A., Fialova L., Soukupova J., Kukal J., Malbohan I., Pitha J. Antibodies against light neurofilaments in multiple sclerosis patients. Acta Neurol. Scand. 2007, 116(2):100-107. available from: PM:17661795.
8. Belogurov A.A., Kurkova I.N., Friboulet A., Thomas D., Misikov V.K., Zakharova M.Y., Suchkov S.V., Kotov S.V., Alehin A.I., Avalle B., Souslova E.A., Morse H.C., Gabibov A.G., Ponomarenko N.A. Recognition and degradation of myelin basic protein peptides by serum autoantibodies: novel biomarker for multiple sclerosis. J. Immunol. 2008, 180(2):1258-1267. available from: PM:18178866.
9. Benjamini Y., Hochberg Y. Controlling the false discovery rate - a practical and powerful approach to multiple testing. J. R. Stat. Soc. B Methodol. 1995, 57(1):289-300. available from: ISI:A1995QE45300017.
10. Berger T., Rubner P., Schautzer F., Egg R., Ulmer H., Mayringer I., Dilitz E., Deisenhammer F., Reindl M. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N. Engl. J. Med. 2003, 349(2):139-145. available from: PM:12853586.
11. Beyer N.H., Milthers J., Bonde Lauridsen A.M., Houen G., Lautrup F.J. Autoantibodies to the proteasome in monosymptomatic optic neuritis may predict progression to multiple sclerosis. Scand. J. Clin. Lab. Invest. 2007, 67(7):696-706. available from: PM:17852796.
12. Blewett M.M. Lipid autoreactivity in multiple sclerosis. Med. Hypotheses 2010, 74(3):433-442. available from: PM:19932569.
13. Brettschneider J., Jaskowski T.D., Tumani H., Abdul S., Husebye D., Seraj H., Hill H.R., Fire E., Spector L., Yarden J., Dotan N., Rose J.W. Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases. J. Neuroimmunol. 2009, 217(1-2):95-101. available from:. http://www.sciencedirect.com/science/article/B6T03-4XK31NY-1/2/f36451e49400b4a2fe8be5612bdeccff.
14. Bronstein J.M., Lallone R.L., Seitz R.S., Ellison G.W., Myers L.W. A humoral response to oligodendrocyte-specific protein in MS: a potential molecular mimic. Neurology 1999, 53(1):154-161. available from: PM:10408552.
15. Carrillo-Vico A., Leech M.D., Anderton S.M. Contribution of myelin autoantigen citrullination to T cell autoaggression in the CNS. J. Immunol. 2010, 184(6):2839-2846. available from: PM:20164413.
16. Celet B., Akman-Demir G., Serdaroglu P., Yentur S.P., Tasci B., van Noort J.M., Eraksoy M., Saruhan-Direskeneli G. Anti-alpha B-crystallin immunoreactivity in inflammatory nervous system diseases. J. Neurol. 2000, 247(12):935-939. available from: PM:11200685.
17. Cepok S., Zhou D., Srivastava R., Nessler S., Stei S., Bussow K., Sommer N., Hemmer B. Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J. Clin. Invest. 2005, 115(5):1352-1360. available from: PM:15841210.
18. Chapman J. The interface of multiple sclerosis and antiphospholipid antibodies. Thromb. Res. 2004, 114(5-6):477-481. available from:. http://www.sciencedirect.com/science/article/B6T1C-4CX6WMD-3/2/9391eab301030ab38559a6ce975b06ae.
19. Cid C., Alvarez-Cermeno J.C., Camafeita E., Salinas M., Alcazar A. Antibodies reactive to heat shock protein 90 induce oligodendrocyte precursor cell death in culture. Implications for demyelination in multiple sclerosis. FASEB J. 2004, 18(2):409-411. available from: PM:14688203.
20. Cid C., Garcia-Villanueva M., Salinas M., Alcazar A. Detection of anti-heat shock protein 90 [beta] (Hsp90[beta]) antibodies in cerebrospinal fluid. J. Immunol. Methods 2007, 318(1-2):153-157. available from:. http://www.sciencedirect.com/science/article/B6T2Y-4M4TM1T-2/2/b48fca7637db6c44c41c49bac5352188.
21. Cruz M., Olsson T., Ernerudh J., Hojeberg B., Link H. Immunoblot detection of oligoclonal anti-myelin basic protein IgG antibodies in cerebrospinal fluid in multiple sclerosis. Neurology 1987, 37(9):1515-1519. available from: PM:2442667.
22. Dennis G., Sherman B.T., Hosack D.A., Yang J., Gao W., Lane H.C., Lempicki R.A. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003, 4(5):3. available from: PM:12734009.
23. Ehling R., Lutterotti A., Wanschitz J., Khalil M., Gneiss C., Deisenhammer F., Reindl M., Berger T. Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosis. Mult. Scler. 2004, 10(6):601-606. available from: PM:15584481.
24. Eikelenboom M.J., Petzold A., Lazeron R.H., Silber E., Sharief M., Thompson E.J., Barkhof F., Giovannoni G., Polman C.H., Uitdehaag B.M. Multiple sclerosis: neurofilament light chain antibodies are correlated to cerebral atrophy. Neurology 2003, 60(2):219-223. available from: PM:12552034.
25. Frederiksen J.L., Whitaker J.N. Cerebrospinal fluid myelin basic protein-like material in acute monosymptomatic optic neuritis. Acta Neurol. Scand. 1996, 94(5):303-309. available from: PM:8947280.
26. Garg N., Zivadinov R., Ramanathan M., Vasiliu I., Locke J., Watts K., Lema J., Rajeswary J., Munschauer F.E., Ambrus J., Weinstock-Guttman B. Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients. J. Neuroimmunol. 2007, 187(1-2):159-165. available from:. http://www.sciencedirect.com/science/article/B6T03-4NS3671-2/2/27e50109e3809c31051a7dc6d8b64355.
27. Gorczyca W.A., Ejma M., Witkowska D., Misiuk-Hojlo M., Kuropatwa M., Mulak M., Szymaniec S. Retinal antigens are recognized by antibodies present in sera of patients with multiple sclerosis. Ophthalmic Res. 2004, 36(2):120-123. available from: PM:15017109.
28. Greer J.M., Pender M.P. Myelin proteolipid protein: an effective autoantigen and target of autoimmunity in multiple sclerosis. J. Autoimmun. 2008, 31(3):281-287. available from: PM:18502611.
29. Gutjahr C., Murphy D., Lueking A., Koenig A., Janitz M., O'Brien J., Korn B., Horn S., Lehrach H., Cahill D.J. Mouse protein arrays from a TH1 cell cDNA library for antibody screening and serum profiling. Genomics 2005, 85(3):285-296. available from: PM: 15718096.
30. Hohlfeld R., Meinl E., Dornmair K. B- and T-cell responses in multiple sclerosis: novel approaches offer new insights. J. Neurol. Sci. 2008, 274(1-2):5-8. available from:. http://www.sciencedirect.com/science/article/B6T06-4T71B22-3/2/bf40d9a17420170e08926403bfe15b44.
31. Huang d.W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009, 4(1):44-57. available from: PM:19131956.
32. Hueber W., Utz P., Steinman L., Robinson W. Autoantibody profiling for the study and treatment of autoimmune disease. Arthritis Res. 2002, 4(5):290-295.
33. Hussein W.I., Reddy S.S. Prevalence of diabetes in patients with multiple sclerosis. Diabetes Care 2006, 29(8):1984-1985. available from: PM:16873819.
34. Kaushansky N., Eisenstein M., Zilkha-Falb R., Ben Nun A. The myelin-associated oligodendrocytic basic protein (MOBP) as a relevant primary target autoantigen in multiple sclerosis. Autoimmun. Rev. 2010, 9(4):233-236. available from:. http://www.sciencedirect.com/science/article/B6W8V-4X0F3WV-1/2/36f5c248616e755ebe74189204105559.
35. Kolln J., Ren H.M., Da R.R., Zhang Y., Spillner E., Olek M., Hermanowicz N., Hilgenberg L.G., Smith M.A., van den N.S., Qin Y. Triosephosphate isomerase- and glyceraldehyde-3-phosphate dehydrogenase-reactive autoantibodies in the cerebrospinal fluid of patients with multiple sclerosis. J. Immunol. 2006, 177(8):5652-5658. available from: PM:17015754.
36. 3dingen H.C., Genain C.P. Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis. Proc. Natl. Acad. Sci. 2006, 103(7):2280-2285. available from:. http://www.pnas.org/cgi/content/abstract/103/7/2280.
37. Lefranc D., Almeras L., Dubucquoi S., de Seze J., Vermersch P., Prin L. Distortion of the self-reactive IgG antibody repertoire in multiple sclerosis as a new diagnostic tool. J. Immunol. 2004, 172(1):669-678. available from: PM:14688380.
38. Lennon V.A., Wingerchuk D.M., Kryzer T.J., Pittock S.J., Lucchinetti C.F., Fujihara K., Nakashima I., Weinshenker B.G. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004, 364(9451):2106-2112. available from: PM:15589308.
39. Lily O., Palace J., Vincent A. Serum autoantibodies to cell surface determinants in multiple sclerosis: a flow cytometric study. Brain 2004, 127(Pt 2):269-279. available from: PM:14662514.
40. Lionel A., de Seze J., Didier L., Sandrine F.N., Sylvain D., Patrick V., Lionel P. Evolution of self-reactive IgG antibody repertoires in patients with relapsing-remitting multiple sclerosis. Immunol. Lett. 2005, 97(1):55-62. available from: PM:15626476.
41. Lolli F., Mulinacci B., Carotenuto A., Bonetti B., Sabatino G., Mazzanti B., D'Ursi A.M., Novellino E., Pazzagli M., Lovato L., Alcaro M.C., Peroni E., Pozo-Carrero M.C., Nuti F., Battistini L., Borsellino G., Chelli M., Rovero P., Papini A.M. An N-glucosylated peptide detecting disease-specific autoantibodies, biomarkers of multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(29):10273-10278. available from: PM:16014416.
42. Lolli F., Mazzanti B., Pazzagli M., Peroni E., Alcaro M.C., Sabatino G., Lanzillo R., Brescia Morra V., Santoro L., Gasperini C. The glycopeptide CSF114(Glc) detects serum antibodies in multiple sclerosis. J. Neuroimmunol. 2005, 167(1-2):131-137. available from:. http://www.sciencedirect.com/science/article/B6T03-4GR33K1-1/2/a86ed590f478c22dbca054304fd3a83b.
43. Lueking A., Possling A., Huber O., Beveridge A., Horn M., Eickhoff H., Schuchardt J., Lehrach H., Cahill D.J. A nonredundant human protein chip for antibody screening and serum profiling. Mol. Cell. Proteomics 2003, 2(12):1342-1349. available from PM: 14517340.
44. Lueking A., Huber O., Wirths C., Schulte K., Stieler K.M., Blume-Peytavi U., Kowald A., Hensel-Wiegel K., Tauber R., Lehrach H., Meyer H.E., Cahill D.J. Profiling of alopecia areata autoantigens based on protein microarray technology. Mol. Cell. Proteomics 2005, 4(9):1382-1390. available from: PM:15939964.
45. Marconi S., Acler M., Lovato L., De Toni L., Tedeschi E., Anghileri E., Romito S., Cordioli C., Bonetti B. Anti-GD2-like IgM autoreactivity in multiple sclerosis patients. Mult. Scler. 2006, 12(3):302-308. available from: PM:16764343.
46. Marta C.B., Oliver A.R., Sweet R.A., Pfeiffer S.E., Ruddle N.H. Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiology. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(39):13992-13997. available from: PM:16172404.
47. Maudsley S., Martin B., Luttrell L.M. G protein-coupled receptor signaling complexity in neuronal tissue: implications for novel therapeutics. Curr. Alzheimer Res. 2007, 4(1):3-19. available from: PM:17316162.
48. Mayo I., Arribas J., Villoslada P., Alvarez D.R., Rodriguez-Vilarino S., Montalban X., De Sagarra M.R., Castano J.G. The proteasome is a major autoantigen in multiple sclerosis. Brain 2002, 125(Pt 12):2658-2667. available from: PM:12429593.
49. Menge T., Lalive P.H., von Budingen H.C., Cree B., Hauser S.L., Genain C.P. Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis. J. Allergy Clin. Immunol. 2005, 116(2):453-459. available from: PM:16083805.
50. Miesbach W., Gilzinger A., Gokpinar B., Claus D., Scharrer I. Prevalence of antiphospholipid antibodies in patients with neurological symptoms. Clin. Neurol. Neurosurg. 2006, 108(2):135-142. available from: PM:16412834.
51. Moller J.R., Johnson D., Brady R.O., Tourtellotte W.W., Quarles R.H. Antibodies to myelin-associated glycoprotein (MAG) in the cerebrospinal fluid of multiple sclerosis patients. J. Neuroimmunol. 1989, 22(1):55-61. available from: PM:2465313.
52. Mycko M.P., Cwiklinska H., Szymanski J., Szymanska B., Kudla G., Kilianek L., Odyniec A., Brosnan C.F., Selmaj K.W. Inducible heat shock protein 70 promotes myelin autoantigen presentation by the HLA class II. J. Immunol. 2004, 172(1):202-213. available from: PM:14688327.
53. Niehaus A., Shi J., Grzenkowski M., Diers-Fenger M., Archelos J., Hartung H.P., Toyka K., Bruck W., Trotter J. Patients with active relapsing-remitting multiple sclerosis synthesize antibodies recognizing oligodendrocyte progenitor cell surface protein: implications for remyelination. Ann. Neurol. 2000, 48(3):362-371. available from: PM:10976643.
54. Olsson T., Baig S., Hojeberg B., Link H. Antimyelin basic protein and antimyelin antibody-producing cells in multiple sclerosis. Ann. Neurol. 1990, 27(2):132-136. available from: PM:1690527.
55. Polman C.H., Reingold S.C., Edan G., Filippi M., Hartung H.P., Kappos L., Lublin F.D., Metz L.M., McFarland H.F., O'Connor P.W., Sandberg-Wollheim M., Thompson A.J., Weinshenker B.G., Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann. Neurol. 2005, 58(6):840-846. available from: PM:16283615.
56. Quintana F.J., Farez M.F., Viglietta V., Iglesias A.H., Merbl Y., Izquierdo G., Lucas M., Basso A.S., Khoury S.J., Lucchinetti C.F., Cohen I.R., Weiner H.L. Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(48):18889-18894. available from: PM:19028871.
57. Rand K.H., Houck H. Improved methods for the application of random peptide phage libraries to the study of the oligoclonal bands in cerebrospinal fluid of patients with multiple sclerosis. J. Neurosci. Meth. 2000, 101(2):131-139. available from: PM:10996373.
58. Rawes J.A., Calabrese V.P., Khan O.A., DeVries G.H. Antibodies to the axolemma-enriched fraction in the cerebrospinal fluid and serum of patients with multiple sclerosis and other neurological diseases. Mult. Scler. 1997, 3(6):363-369. available from: PM:9493635.
59. Reder A.T., Oger J.J. Anti-myelin oligodendrocyte glycoprotein antibodies in multiple sclerosis. Neurology 2004, 62(11):1922-1923. available from: PM:15184588.
60. Reindl M., Khantane S., Ehling R., Schanda K., Lutterotti A., Brinkhoff C., Oertle T., Schwab M.E., Deisenhammer F., Berger T., Bandtlow C.E. Serum and cerebrospinal fluid antibodies to Nogo-A in patients with multiple sclerosis and acute neurological disorders. J. Neuroimmunol. 2003, 145(1-2):139-147. available from: PM:14644040.
61. Sadatipour B.T., Greer J.M., Pender M.P. Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. Ann. Neurol. 1998, 44(6):980-983. available from: PM:9851447.
62. Salzer J., Svenningsson A., Sundstrom P. Neurofilament light as a prognostic marker in multiple sclerosis. Mult. Scler. 2010, 16(3):287-292. available from:. http://msj.sagepub.com/cgi/content/abstract/1352458509359725v1.
63. Schwarz M., Spector L., Gortler M., Weisshaus O., Glass-Marmor L., Karni A., Dotan N., Miller A. Serum anti-Glc(alpha1,4)Glc(alpha) antibodies as a biomarker for relapsing-remitting multiple sclerosis. J. Neurol. Sci. 2006, 244(1-2):59-68. available from: PM:16480743.
64. Silber E., Semra Y.K., Gregson N.A., Sharief M.K. Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit. Neurology 2002, 58(9):1372-1381. available from: PM:12011283.
65. Somers V., Govarts C., Hellings N., Hupperts R., Stinissen P. Profiling the autoantibody repertoire by serological antigen selection. J. Autoimmun. 2005, 25(3):223-228. available from: PM:16256306.
66. Somers V., Govarts C., Somers K., Hupperts R., Medaer R., Stinissen P. Autoantibody profiling in multiple sclerosis reveals novel antigenic candidates. J. Immunol. 2008, 180(6):3957-3963. available from: PM:18322204.
67. Somers K., Govarts C., Stinissen P., Somers V. Multiplexing approaches for autoantibody profiling in multiple sclerosis. Autoimmun. Rev. 2009, 8(7):573-579. available from:. http://www.sciencedirect.com/science/article/B6W8V-4VK02N7-1/2/58de78020030dad095b4f1f993c67a92.
68. Statnikov A., Aliferis C.F., Tsamardinos I., Hardin D., Levy S. A comprehensive evaluation of multicategory classification methods for microarray gene expression cancer diagnosis. Bioinformatics 2005, 21(5):631-643. available from: PM:15374862.
69. Sueoka E., Yukitake M., Iwanaga K., Sueoka N., Aihara T., Kuroda Y. Autoantibodies against heterogeneous nuclear ribonucleoprotein B1 in CSF of MS patients. Ann. Neurol. 2004, 56(6):778-786. available from: PM:15497154.
70. Sun J.B., Olsson T., Wang W.Z., Xiao B.G., Kostulas V., Fredrikson S., Ekre H.P., Link H. Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls. Eur. J. Immunol. 1991, 21(6):1461-1468. available from: PM:1710567.
71. Susumu Chiba, Shin-ichi Yokota, Kazumi Yonekura, Shingo Tanaka, Hiroyasu Furuyama, Hiroshi Kubota, Nobuhiro Fujii, Hiroyuki Matsumoto Autoantibodies against HSP70 family proteins were detected in the cerebrospinal fluid from patients with multiple sclerosis. J. Neurol. Sci. 2006, 241:39-43.
72. Susumu Chiba, Shin-ichi Yokota, Kazumi Yonekura, Shingo Tanaka, Hiroyasu Furuyama, Hiroshi Kubota, Nobuhiro Fujii, Hiroyuki Matsumoto Autoantibodies against HSP70 family proteins were detected in the cerebrospinal fluid from patients with multiple sclerosis. J. Neurol. Sci. 2006, 241:39-43. available from: file://F:\Dokumenter\Sklerose\Sklerose_RefID145.pdf.
73. Svarcova J., Fialova L., Bartos A., Steinbachova M., Malbohan I. Cerebrospinal fluid antibodies to tubulin are elevated in the patients with multiple sclerosis. Eur. J. Neurol. 2008, 15(11):1173-1179. available from: PM:18973612.
74. Teunissen C.E., Dijkstra C., Polman C. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol. 2005, 4(1):32-41. available from: PM:15620855.
75. Van Noort J.M., Verbeek R., Meilof J.F., Polman C.H., Amor S. Autoantibodies against alpha B-crystallin, a candidate autoantigen in multiple sclerosis, are part of a normal human immune repertoire 1. Mult. Scler. 2006, 12(3):287-293. available from: PM:16764341.
76. Villar L.M., Sadaba M.C., Roldan E., Masjuan J., Gonzalez-Porque P., Villarrubia N., Espino M., Garcia-Trujillo J.A., Bootello A., Alvarez-Cermeno J.C. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J. Clin. Invest. 2005, 115(1):187-194. available from: PM:15630459.
77. Villar L.M., Masterman T., Casanova B., Gomez-Rial J., Espino M., Sadaba M.C., Gonzalez-Porque P., Coret F., Alvarez-Cermeno J.C. CSF oligoclonal band patterns reveal disease heterogeneity in multiple sclerosis. J. Neuroimmunol. 2009, 211(1-2):101-104. available from: PM:19443047.
78. Vogt M.H., Teunissen C.E., Iacobaeus E., Heijnen D.A., Breij E.C., Olsson T., Brundin L., Killestein J., Dijkstra C.D. Cerebrospinal fluid anti-myelin antibodies are related to magnetic resonance measures of disease activity in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2009, 80(10):1110-1115. available from: PM:18931010.
79. Walsh M.J., Murray J.M. Dual implication of 2',3'-cyclic nucleotide 3' phosphodiesterase as major autoantigen and C3 complement-binding protein in the pathogenesis of multiple sclerosis. J. Clin. Invest. 1998, 101(9):1923-1931. available from: PM:9576757.
80. Warren K.G., Catz I. Diagnostic value of cerebrospinal fluid anti-myelin basic protein in patients with multiple sclerosis. Ann. Neurol. 1986, 20(1):20-25. available from: PM:2427010.
81. Warren K.G., Catz I. Relative frequency of autoantibodies to myelin basic protein and proteolipid protein in optic neuritis and multiple sclerosis cerebrospinal fluid. J. Neurol. Sci. 1994, 121(1):66-73. available from: PM:7510787.
82. Williamson R.A., Burgoon M.P., Owens G.P., Ghausi O., Leclerc E., Firme L., Carlson S., Corboy J., Parren P.W., Sanna P.P., Gilden D.H., Burton D.R. Anti-DNA antibodies are a major component of the intrathecal B cell response in multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2001, 98(4):1793-1798. available from: PM:11172030.
83. Zanetta J.P., Warter J.M., Kuchler S., Marschal P., Rumbach L., Lehmann S., Tranchant C., Reeber A., Vincendon G. Antibodies to cerebellar soluble lectin CSL in multiple sclerosis. Lancet 1990, 335(8704):1482-1484. available from: PM:1972431.